06:46 AM EDT, 08/07/2024 (MT Newswires) -- Novo Nordisk ( NVO ) reported Q2 earnings Wednesday of 4.49 Danish kroner ($0.66) per diluted American depositary receipt, up from 4.32 kroner a year earlier.

Analysts polled by Capital IQ expected 4.97 kroner.

Net sales for the quarter was 68.06 billion kroner, up from 54.3 billion kroner a year earlier.

Analysts polled by Capital IQ expected 68.56 billion kroner.

Novo Nordisk ( NVO ) said it now expects 2024 sales growth to be 22% to 28% at constant exchange rates, raising the previous guidance 19% to 27%. Analysts polled by Capital IQ are looking for full-year sales of 292.4 billion kroner.

The company also cut its outlook for 2024 operating profit growth to 20% to 28% at constant exchange rates, from 22% to 30% previously.

Shares of the company were down 2.7% in recent Wednesday premarket activity.

Price: 126.55, Change: -3.57, Percent Change: -2.74